Abstract | Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.
Although they were discovered more than 40 years ago, natural killer (NK) cells have recently been attracting attention for their potential in immune-based therapies. Initially believed to be just an annoying background activity in cytotoxicity assays or an artefact, NK cells are now considered to be an important part of the immune system by controlling microbial infections and tumour progression. Recently, it has been appreciated that NK cells are the founding member of the innate lymphoid cell (ILC) family 1 . Although the ILC family subtypes are characterized primarily by their signature cytokine secretion profiles -ILC1 produces interferon-γ (IFNγ), ILC2 produces interleukin-5 (IL-5) and IL-13, and ILC3 produces IL-17 and IL-22 -the NK cells are the predominant population with specialized cytolytic function.
In patients and animal models, impaired NK cells or NK cell deficiency have been associated not only with recurring virus infections, but also with an increased incidence of various types of cancer 2 . NK cell functions are tightly regulated by a balance between activating and inhibitory signals (FIG. 1a) delivered by a multitude of receptors expressed at the cell surface 3 (TABLE 1) . Using these immune receptors, NK cells are able to recognize and then spontaneously kill 'stressed' cells, such as infected or tumour cells, without prior sensitization. Indeed, these abnormal cells can initiate NK cell effector functions, including cytotoxicity, cytokine production and proliferation, either through the loss of self identifying molecules such as major histocompatibility complex (MHC) class I that bind to inhibitory receptors on the NK cells (detection of 'missing self ' , FIG. 1b) or by upregulating the expression of ligands for activating receptors on the NK cells that can overcome the inhibitory signals (FIG. 1c) . Furthermore, as opposed to other immune cells that require a considerable length of time to acquire cytolytic activity, NK cells are 'ready to kill' , which provides a powerful tool for use in immuno therapeutic approaches. In this Review, we describe the established role of NK cells in tumour surveillance, as well as that of other immune cells expressing NK cell receptors that may contribute to their antitumour immune responses. Given the successful anticancer therapeutic approaches involving blockade of T cell-directed immune checkpoints, we discuss how these and new combination strategies could also affect the antitumour functions of NK cells. To conclude, we focus on recent progress in genetic engineering of immune cells, and how this field could benefit from targeting NK cells and their receptors. 4 and the Ly49 (also known as KLRA) receptors in mice 5 . The KIR and Ly49 receptors are generated by a multi genic family of polymorphic genes that encode both inhibitory and activating receptors 4, 5 . Another receptor family conserved in both mice and humans is the CD94 (also known as KLRD1)-NKG2 receptor system. In this family, the CD94 receptor forms a disulfide-linked heterodimer with the inhibitory NKG2A receptor or with the activating NKG2C receptor 6 . Unlike KIRs and Ly49, the CD94-NKG2 receptors are invariant and recognize a relatively non-polymorphic MHC class I ligand, human leukocyte antigen-E (HLA-E) in humans [7] [8] [9] and Qa1 in mice 10 . The inhibitory KIR, Ly49 and CD94-NKG2A receptors function to detect self-MHC class I ligands on healthy cells and prevent or dampen NK cell activation (FIG. 1a) . Activating receptors in these families may recognize pathogen-encoded ligands or detect alterations in the peptide repertoire in MHC class I molecules, which results in NK cell activation 
γδ T cells
A subset of T cells that express a distinct T cell receptor (TCR) composed of one γ-chain and one δ-chain, instead of the α-and β-chains that comprise the TCR on the majority of T cells. Like natural killer cells, they are considered to be a bridge between innate and adaptive immunity.
NK cells use inhibitory receptors to prevent the killing of healthy cells, whereas they need strong activating signals to initiate an immune response against infected cells or tumour cells (FIG. 1b,c) . NK cells possess numerous receptors that can trigger their effector functions when they are engaged alone or in combination 14 . NKG2D (also known as CD314 and KLRK1), the natural cytotoxicity receptors (NCRs), DNAM1 (also known as CD226) and CD16 are the best-characterized activating NK cell receptors implicated in immune responses against cancer. NKG2D is a particularly important and well-studied receptor, which is expressed by all NK cells, as well as by CD8 + T cells and γδ T cells 15 . This type II transmembrane-anchored protein has unique properties, which include binding to an extensive array of ligands. In humans, NKG2D ligands (NKG2DLs) are MHC class I polypeptide-related sequence A (MICA), MICB, retinoic acid early transcript 1E protein (RAET1E), RAET1G, RAET1H, RAET1I, RAET1L and RAET1N (also known as ULBP1-ULBP6), whereas in mice its ligands are the RAE1 family (α, β, γ, δ and ε), the histocompatibility antigen 60 (H60) family (H60a, H60b and H60c) and mouse UL16-binding protein-like transcript 1 (MULT1) 16, 17 . These ligands are not present on the cell surface of most healthy tissues, but can be expressed on rapidly proliferating cells, infected cells, transformed cells and tumour cells 17 . Regulation of the NKG2DLs is a very complex process that can involve transcriptional, translational and post-translational control, and there are no general rules that apply for the induction and expression of the different NKG2DLs in different cell types or tumours 16, 17 . Some viruses and tumour cells have developed escape mechanisms to circumvent NKG2D-mediated immunosurveillance, for example, by ligand shedding, intracellular retention of ligands and induction of ligands on neighbouring bystander cells, which demonstrates the importance of this interaction during immune responses 16, 17 . NCRs are another family of activating receptors that were discovered on NK cells in the 1990s, and include three receptors: NKp30 (also known as NCR3 and CD337), NKp44 (also known as NCR2 and CD336) and NKp46 (also known as NCR1 and CD335) 18 . NKp30 (REF. 19 ) and NKp46 (REF. 20) transmit their activating signal by associating with the immunoreceptor tyrosinebased activation motif (ITAM)-bearing adaptor protein CD3ζ, and the high-affinity IgE receptor-γ (FcεRIγ), whereas NKp44 associates with DAP12 (also known as TYROBP) 21 . NKp46 and NKp30 are expressed constitutively on NK cells, but NKp44 is expressed only after activation of NK cells. NKp46 is highly conserved among species including in mice 22 , whereas NKp30 and NKp44 are not present in inbred mice 23 , which limits the ability to probe their in vivo function. A wide variety of NCR ligands have been reported, including ligands encoded by genes from viruses, bacteria and parasites; however, most of these are not well defined 18 (TABLE I) . Although as yet not characterized, NCR ligands have been detected on many tumour cells and some healthy tissues 18 . DNAM1 is an activating receptor expressed by NK cells, subsets of T cells and myeloid cells 24 . Its ligands are CD112 (also known as PVRL2 and nectin 2) and CD155 (also known as PVR), which are members of the Nectin family of molecules and are broadly distributed on haematopoietic and non-haematopoietic cells, including on many tumour cells. DNAM1 is involved in NK cell-mediated killing of certain tumours, including melanomas 25 , and Cd226 −/− mice are more susceptible to primary and transplantable tumours 26, 27 . Two other inhibitory receptors, T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD96, also bind to DNAM1 ligands and oppose DNAM1 function 24, 28 . TIGIT can disrupt DNAM1 signalling by interacting with it in cis to form heterodimers, and blockade of TIGIT with mono clonal antibodies augments the antitumour and antiviral activity of NK cells and T cells in vivo in mouse models of cancer and viral infection 29 . A potent activator of NK cells is CD16 (also known as FcγRIIIA), which is expressed predominantly on the CD56 dim subset of NK cells in humans and on most mouse NK cells 30 . This receptor recognizes the constant region (Fc) of IgG antibodies, predominantly IgG1 in humans, and is responsible for antibody-dependent cell-mediated cytotoxicity (ADCC) FIG. 1d) . Although the role of CD16 in NK cell-mediated immunosurveillance in mouse models has not been addressed, allelic polymorphisms of FCGR3A (which encodes CD16) in humans that affect the affinity of the receptor have been correlated with the efficacy of rituximab (anti-CD20) antibody therapy 31 . CD16 is also expressed on activated macrophages, thus both NK cells and macrophages might contribute to the therapeutic benefit of ADCC in antibody-mediated cancer therapies.
NK cell functions
Mature NK cells are morphologically characterized as large granular lymphocytes. These granules contain both perforin (a membrane-disrupting protein) and granzymes (a family of proteolytic enzymes), which are responsible for NK cell-mediated killing 32 . When NK cells interact with target cells, an immunological synapse forms, by which these granules are exocytosed 33 , leading to the specific lysis of the target cell. Additionally, NK cells are able to kill tumour cells by using molecules in the tumour necrosis factor (TNF) family. NK cells express both soluble and membranebound TNF, and activation of NK cells induces death-inducing ligands, such as FAS ligand (FASLG; also known as TNFSF6) and TNF-related apoptosisinducing ligand (TRAIL; encoded by TNFSF10) at the NK cell surface 34 . When bound to these ligands, death receptors on target cells (for example, FAS) can activate the caspase enzymatic cascade that 14 . The bestcharacterized cytokine produced by NK cells is IFNγ, but they can also secrete numerous interleukins (for example, IL-10), TNF, growth factors (for example, granulocyte-macrophage colony-stimulating factor (GM-CSF)) 37 and chemokines (for example, chemokine (C-C motif) ligand 3 (CCL3), CCL4 and CCL5) Tumour surveillance by NK cells NK cells were first implicated in tumour immunosurveillance in the 1980s, when several studies reported a higher incidence of cancers in individuals with defective NK cell function caused by genetic disorders such as Chédiak-Higashi syndrome and X-linked lymphoproliferative syndrome 40, 41 . During the same period, increased tumour growth and metastasis were described in mutant mice with impaired NK cell activity 42 and in mice treated with an NK cell-depleting antibody 43 . Numerous studies then found decreased NK cell function in cancer patients [44] [45] [46] or their families 47, 48 , including in a landmark long-term epidemiological study reporting that subjects with low NK cell activity had a higher risk of developing various types of cancer 49 . NK cell deficiencies 2 , characterized by the absence of NK cells or NK cell function, and caused by genetic mutations in genes such as GATA2 (REF. 50) or MCM4 (REF. 51 ), lead to higher rates of malignancy. These primary immunodeficiencies affecting NK cells indicate how important these cells are in tumour immune surveillance. However, these immuno deficiencies affect other immune cells in addition to NK cells, and the relationship between increased cancer risk and low NK cell activity (frequently measured by in vitro cytotoxicity assays using the K562 leukaemia cell line as the target) is only correlative. NK cells have been shown to control the growth and metastasis of transplantable tumours in numerous mouse models by antibody depletion of NK cells 52 . However, a significant limitation to these studies has been the ability to selectively ablate NK cells for the long periods of time that are often necessary to establish primary tumours. There are no truly NK cell-specific molecules that can serve as targets for genetic or antibody-mediated ablation of NK cells. A recent comprehensive transcriptional profiling study of mouse leukocyte populations by the Immunological Genome Consortium revealed that essentially all genes expressed by NK cells are also expressed by other immune cell types, usually by subsets of T cells or other ILCs 53 . In many models, mouse NK cells are depleted using an antibody against NK1.1 (also known as KLRB1C); however, NK1.1 is expressed on invariant natural killer T cells (iNKT cells) and some activated CD8 + T cells, as well as some ILCs. Perhaps the most NK cell-restricted marker is NKp46, but this receptor is also expressed by a subset of γδ T cells and other ILC populations 54 . Although RAG-deficient (for example, Rag1 −/− or Rag2
) mice can be used to exclude B and T cell contributions to anti tumour effects, the shared expression of many molecules by NK cells and other ILC subsets 55 must be considered. Although NK cells have been documented to infiltrate primary tumours in mice and humans, they typically comprise only a minor population, raising questions about their importance 56 . Given the paucity of NK cells usually detected in solid tumours, and their relative abundance in the circulation, it has been speculated that the predominant role of NK cells might be to prevent meta stasis of tumours 43 . However, even if NK cells fail to accumulate in solid tumours, this does not exclude that they significantly contribute to antitumour immune responses by their cytolytic functions and by secreting chemokines or cytokines that attract or activate tumour-infiltrating T cells or myeloid cells. Many new reagents and imaging technologies are being developed that provide more sensitive and dynamic methods of probing the leukocyte populations that infiltrate tumours, which should provide important insights into the recruitment and function of NK cells within tumour sites.
What renders tumours susceptible to NK cellmediated attack? As noted above, it is the net balance of activating and inhibitory signals that regulates whether an NK cell attacks and eliminates a potential target cell. As demonstrated by the ability of NK cells in healthy mice to reject transferred splenocytes from β2-microglobulin-deficient (B2m −/− ) mice 57 , normal cells express relevant ligands for activating receptors on NK cells to initiate killing of these cells if unopposed by signals from the NK cell inhibitory receptors for MHC class I. Therefore, NK cells can eliminate tumours that downregulate expression of MHC class I (FIG. 1b) , Box 1 | Antibody-dependent cell-mediated cytotoxicity Natural killer (NK) cells express CD16 (or FcγRIIIA), a cell surface receptor for the highly conserved Fc portion of immunoglobulin G (IgG) antibodies. When human IgG1 antibodies bind to specific antigens displayed by infected or transformed cells, these antibodies are recognized by CD16 and trigger NK cell activation and killing of the antibody-coated target cells. This mechanism is referred to as antibody-dependent cell-mediated cytotoxicity (ADCC). In humans, circulating mature NK cells express CD16 and exhibit potent ADCC effector function. A polymorphism at residue 158 in human CD16 that encodes either valine (higher affinity) or phenylalanine (lower affinity) affects the affinity of binding of CD16 to IgG1 and influences the magnitude of the ADCC response initiated by therapeutic antibodies such as rituximab. Engineering the Fc region of these antibodies in order to increase their affinity for both CD16 variants is a promising avenue for improving ADCC responses against tumours in all patients. Nature Reviews | Cancer possibly in response to selective pressure exerted by CD8 + T cells, although still displaying one or several ligands for an activating NK cell receptor. Although most tumours have retained expression of MHC class I, it is impossible to know the frequency with which nascent tumours losing MHC class I are eliminated by NK cells before becoming established. Alternatively, NK cells can kill tumour cells that retain full expression of MHC class I if they have upregulated ligands that engage activating NK cell receptors, thus overriding the inhibitory signals (FIG. 1c) .
Perhaps the best-characterized ligands for an activating NK receptor that are abundantly expressed on transformed cells from various origins 58 are the NKG2D ligands 17 . NK cell activation induced by NKG2D ligand expression on tumour cells is sufficient to overcome inhibitory signals delivered by MHC class I receptors, thereby enabling NK cells to eliminate tumours expressing normal levels of MHC class I 59, 60 . Furthermore, mice deficient for NKG2D (Klrk1 −/− ), or treated with an NKG2D-neutralizing antibody, are more susceptible to primary tumorigenesis 61, 62 , confirming the crucial role of NKG2D in tumour immunosurveillance, although it has not yet been established whether NKG2D-mediated protection is conferred by NK cells, T cells or both. One of the mechanisms used by tumour cells to evade this surveillance is the shedding of NKG2DLs through cleavage by metalloproteinases, which decreases the amount of ligand at the tumour cell surface [63] [64] [65] [66] [67] [68] (FIG. 2) . Soluble NKG2DLs have been found in the sera of patients with many different types of cancer 69 and might be used as a diagnostic marker 70 . Another novel escape mechanism involves the induction of NKG2DLs on healthy host myeloid cells by soluble factors (such as lactate dehydrogenase) secreted by tumour cells 71 . Chronic stimulation of NKG2D by ligand-bearing cells, whether on tumours or on healthy host cells, results in down regulation of NKG2D and desensitization of the NKG2D pathway, thereby impairing NKG2D-dependent tumour immunosurveillance 72, 73 . Therapeutic strategies to preserve or induce NKG2DL expression on tumours and prevent desensitization of the NKG2D receptor on NK cells and T cells provide an attractive target for immunotherapy. Recent work in a mouse model suggests that a soluble high-affinity NKG2DL, MULT1, can stabilize expression of NKG2D on the surface of NK cells and augment NKG2D-dependent NK cell antitumour activity 74 . Several other mechanisms that enable tumours to evade NK cell-mediated surveillance have been documented. For example, tumours that activate platelets can avoid NK cell recognition, either directly by disrupting activating ligand expression 75 and displaying ligands for NK cell inhibitory receptors 76, 77 , or indirectly by releasing immunoregulatory factors, such as transforming growth factor-β (TGFβ) 78 (FIG. 2) . Additionally, tumours themselves secrete immunomodulatory molecules that compromise the activity of immune cells in general, and NK cells in particular. Factors that can suppress NK cell effector functions include TGFβ 79 , prostaglandin E 2 (REFS 80,81), indoleamine 2,3-dioxygenase 81 and adenosine 82 (FIG. 2) . This may not only impair NK cell function, but also block their maturation process, for example, by downregulating expression of the IL-15 receptor 83 . Tumours can also produce IL-10, a cytokine known mainly for its anti-inflammatory and immunosuppressive properties; however, IL-10 has also been shown to display immunostimulatory activity, especially on NK cells, in some cancer settings 84, 85 . The NCRs have been implicated in antitumour immune responses on the basis of the ability of monoclonal anti bodies against these receptors to block human NK cell killing of various tumour cell lines using in vitro cyto toxicity assays 86 . In many cases, combining the anti bodies against NKp30, NKp44 and NKp46 demonstrated more efficient blocking of lysis of tumours than the same antibodies individually, implying the existence of different ligands on the target cells. Fc-fusion proteins containing the extracellular domains of the NCRs bind to a broad array of tumour cells, as well as healthy cells, suggesting that the ligands of these receptors are widely expressed 87, 88 . Several putative ligands expressed by tumours have been proposed for the NCRs (TABLE 1) , including heparan sulfates 18 ; however, the only well-validated cellular ligand of an NCR is B7-H6 (also known as NCR3LG1) 89 , which has recently been co-crystalized with NKp30 (REF. 90 ). B7-H6 is expressed preferentially on tumours, including leukaemias, lymphomas, melanomas and carcinomas 89 , but is induced on healthy Toll-like receptor (TLR)-activated myeloid cells 91 . NKp46-deficient (Ncr1 −/− ) mice have been reported to have an impaired ability to control growth of the PD1.6 lymphoma cell line 92 and metastasis of the B16 melanoma and Lewis lung carcinoma cell lines injected in the footpad or in the tail vein 93 , although NKp46 ligands on these tumours have not been identified. NKp46 has also been implicated in the rejection of glioblastomas induced by infection with Herpes simplex virus in a mouse model 94 . Collectively, the NCRs are an important part of the NK cell repertoire of receptors that provide defence against tumours, and a better understanding of their recognition may suggest new approaches to cancer therapy.
Schreiber and colleagues 95 have demonstrated that, as they evolve in the host, tumours are shaped or edited by encounters with the immune system. Although the adaptive immune system has a major role in editing nascent tumours, there is evidence for immune-based editing by NK cells. Bui and colleagues 39 observed a higher incidence of methylcholanthrene-induced sarcomas in RAG-deficient (Rag2 −/− ) mice lacking the IL-2-receptor-γ chain (Il2rg −/− ), which lack NK cells, compared with Rag2 −/− mice, which possess NK cells, and found that tumours arising in Rag2 −/− Il2rg −/− mice were more immunogenic when transplanted into wild-type immunocompetent mice. Further, they demonstrated that this impairment in tumour immune surveillance was dependent on IFNγ production by NK cells and the activation of macrophages within the tumour microenvironment. There is also evidence for immune-based editing mediated by the DNAM1, NKG2D and NKp46 receptors. DNAM1-deficient (Cd226 −/− ) mice developed significantly more DNAM1 ligand-expressing fibro sarcoma and papilloma cells when induced by methylcholanthrene and DMBA, respectively, than did wild-type mice 26 . Similarly, Smyth and colleagues 96 reported the preferential growth of methylcholanthreneinduced sarcomas expressing high levels of NKG2DLs in perforin-deficient (Prf −/− ) mice compared with wild-type mice, and Guerra et al. 61 have also observed evidence for NKG2D-mediated editing of primary Myc-driven B cell tumours arising in NKG2D-deficient (Klrk1 −/− ) mice compared with wild-type mice. Although methylcholanthrene-induced sarcomas were induced at the same frequency in NKp46-deficient (Ncr1 −/− ) and wild-type mice, ana lysis of cell lines derived from these tumours revealed higher levels of expression of NKp46 ligands (detected by staining with a NKp46-Ig fusion protein) on sarcomas isolated from NKp46-deficient (Ncr1 −/− ) mice 97 . Together, these studies suggest a role for NK cells in the immunoediting of primary tumours; however, because DNAM1, NKG2D and NKp46 are also expressed on T cells and other ILCs, further studies are needed to discriminate the contribution of NK cells and other lymphocytes bearing these receptors.
Although NK cells and NK receptors have been shown to provide host protection, the challenge now is to devise strategies to augment their activity against tumours that have evolved mechanisms to escape detection and elimination by NK cells.
Checkpoint blockade of NK cells
Given their very strong antitumour potential, current immunotherapy approaches could also take advantage of NK cell activity. Recent reports have shown that under some circumstances activated NK cells can express programmed cell death protein 1 (PD1; also known as PDCD1) 98, 99 and cytotoxic T lymphocyteassociated antigen 4 (CTLA4) 100 , which are the target molecules of several US Food and Drug Administration (FDA)-approved cancer immunotherapy drugs (ipilimumab against CTLA4 and nivolumab and pembrolizumab against PD1) that restore T cell activation. A promising study showed that, in patients with multiple myeloma, NK cells express PD1 and that a PD1 antibody (CT-011) could restore NK cell-mediated antitumour activity 101 . Additionally, NK cells are able to potently kill tumour cells treated with a human IgG1 PD1 ligand 1 (PDL1) monoclonal antibody owing to the synergistic effect of the inhibitory PD1-PDL1 interaction being blocked and ADCC induced through the activating CD16 Fc receptor on NK cells 102 . Although the role of CTLA4 in NK cells is unclear 103, 104 , NK cells might have a functional impact in patients treated with CTLA4 antibodies. For example, cytokines produced by activated T cells by CTLA4 blockade therapy might activate NK cells and initiate their antitumour effector functions. CTLA4 can also be expressed on some tumour cells 105 and thus induce ADCC after treatment with CTLA4 anti bodies 106 . Moreover, tumour cells infected with oncolytic viruses, such as Newcastle Disease virus 107 and H-1PV rat parvovirus 108 , have been shown to stimulate NK cells directly by inducing activating ligands on the virus-infected cells. A recent study that tested the combination of CTLA4 blockade and onco lytic virus infection demonstrated that the strong antitumour effect obtained was, in part, dependent on NK cells 109 . Because several antibodies targeting the PD1 and CTLA4 pathways have been approved or are in clinical trials, studying their impact on NK cell activity in more depth is now crucial. Furthermore, given the successes of these immune checkpoint inhibitors, novel approaches are being developed that could use a combination of current and new targets, some of them being expressed by NK cells. 
Alloantigen-specific response
An immune response directed towards polymorphic antigens expressed by cells of the same species, such as those from transplanted cells or tissues.
Graft-versus-host disease
(GVHD). A complication of allogeneic haematopoietic stem cell transplantation that occurs when contaminating T cells present in the graft recognize the recipient cells as foreign and mount an immune response against them.
Adoptive cell transfer
Refers to the administration of autologous or allogeneic cells to a recipient.
Anergic state
Characterized by the unresponsiveness of immune cells as a result of chronic stimulation or other immunosuppressive mechanisms.
Because their interaction with self-MHC class I molecules, which are expressed on every nucleated cell in the host including tumour cells, strongly inhibits NK cell-mediated cytotoxicity, inhibitory KIRs have become a target of choice for direct immune checkpoint blockade of NK cells (FIG. 3a) . IPH2102, a monoclonal antibody that blocks KIR2DL1, KIR2DL2 and KIR2DL3 -three inhibitory KIRs that are specific for all HLA-C molecules -has been shown to increase NK cell activity against tumour cells in vitro 110 , while maintaining tolerance to healthy cells 111 . Because anti-KIR enhanced NK cell-mediated, rituximab-dependent cytotoxicity against lymphomas in vitro and in vivo in KIR transgenic and syngeneic mouse lymphoma models 112 , KIR blockade provides an attractive target for cancer immunotherapy. Further, it should be appreciated that inhibitory KIRs are expressed on a subset of effector and/or memory CD4 + and CD8 + T cells in addition to NK cells, so KIR blockade might augment the antitumour activity of T cells in addition to NK cells. Phase I and Phase II trials in patients with acute myeloid leukaemia (AML) or multiple myeloma have demonstrated that treatment with anti-KIR is safe and has minimal side effects [113] [114] [115] . Although these early trials using anti-KIR as a monotherapy have not demonstrated significant efficacy, one might envisage synergy when it is combined with CTLA4 or PD1 blockade, which are known to induce systemic induction of pro-inflammatory cytokines that may further boost NK cell function.
NKG2A is another inhibitory receptor on NK cells and some T cells that recognizes an MHC class I ligand, HLA-E, and is planned for testing in human cancer patients 116 . Finally, NK cells express T cell Ig mucin receptor 3 (TIM3; also known as HAVCR2) 117 and lymphocyte activation gene 3 (LAG3) 118 , two inhibitory immune checkpoint receptors currently under development as potent targets when combined with PD1 blockade [119] [120] [121] , promising that NK cell antitumour activity might also be unleashed by these new immunotherapy combinations.
An alternative strategy to blocking inhibitory receptors with monoclonal antibodies for cancer therapy is to use agonist antibodies to augment the effector functions of T cells or NK cells. CD137 (also known as 4-1BB and TNFRSF9) is expressed on both cytotoxic T cells and activated NK cells, and agonist mono clonal antibodies augment antitumour activity in mouse models 122 , although there are conflicting data on the role of CD137 in NK cell activation 123 . Agonist CD137 antibodies enhance the human NK cell-mediated killing of breast tumours 124 and B cell lymphomas 125 induced by trastuzumab and rituximab, respectively. Although agonist CD137 antibodies showed significant toxicities when used at high doses in the early clinical trials 126 , lower doses might serve to increase antitumour efficacy when combined with other checkpoint blockade therapeutics or with tumour-specific antibodies that induce ADCC. However, care must be taken when combining agonist antibodies against co-stimulatory receptors, as this might increase off-target toxicities.
Other co-stimulatory molecules that have shown efficacy in mouse tumour models that are being considered as targets for agonist antibodies in cancer therapy include glucocorticoid-induced TNFR-related protein (GITR; also known as CD357 and TNFRSF18) and CD27 (REF. 127 ), both of which are expressed on NK cells. Combination of these agonists of NK cell co-stimulatory receptors with blockade of inhibitory receptors expressed by T cells and/or NK cells is a promising approach in future cancer therapies.
Using NK cells for cancer therapy
The first clinical use of NK cells involved infusing IL-2-activated (lymphokine-activated killer cells (LAK cells)) into cancer patients in the 1980s 128 . In vitro studies had documented the ability of activated NK cells to kill autologous tumours in patients, but the clinical efficacy of LAK therapy was limited by the toxicity of IL-2 and possibly by the IL-2-driven expansion of T regulatory (T Reg ) cells, which were unknown at that time. Further, the inhibitory receptors on NK cells, such as KIR and NKG2A, may limit their antitumour potential. The first evidence for the clinical benefit of NK cells was reported in 2002 by Velardi and colleagues 129 who observed that patients with AML who received allogeneic bone marrow transplants that were mismatched for KIR and HLA-C experienced a significantly lower rate of relapse, suggesting that the donor-derived NK cells were mediating an alloantigen-specific response against the AML without causing graft-versus-host disease (GVHD) (FIG. 3b) . This strategy was extended by the adoptive cell transfer of in vitro activated allogeneic KIR-mismatched NK cells into patients with AML 130 and autologous NK cells into patients with malignant gliomas 131 , which demonstrated partial, but modest, success. Results have seemed most promising when there is evidence of persistence and expansion of the NK cells after infusion 130 . A recent study has reported severe GVHD in some cancer patients given T celldepleted allogeneic haemato poietic stem cell transplants infused with allogeneic NK cells pre-activated in vitro with IL-15 and TNFSF9 (also known as 4-1BBL) 132 . Although it is not known whether the GVHD was caused directly by the NK cells, or the NK cells induced a T cell-mediated GVHD response, this outcome was surprising given that NK cells have not been shown to cause GVHD in previous human clinical trials or in preclinical mouse models.
Although the therapeutic efficiency of adoptively transferred IL-2-activated NK cells seems to be limited, recent studies have reported that mouse NK cells activated in vitro with a combination of IL-12, IL-15 and IL-18 survived longer after adoptive cell transfer than naive cells and produced more IFNγ after stimulation 133 . These pre-activated NK cells had better effector functions in vitro, as well as enhanced proliferation, tumour infiltration and tumour control in vivo when tested in mouse models of lymphoma and melanoma 134, 135 . Furthermore, recent work by Ardolino et al. 136, 137 showed that treatment with these cytokines in vivo reversed the tumour-induced anergic state of NK Several challenges must be overcome to optimize the use of NK cells in cancer therapy, including blocking the inhibitory receptors that dampen NK cell activation (FIG. 3a) , eliminating T Reg cells that suppress their function, enabling NK cells to traffic into solid tumours, neutrali zing immunosuppressive cytokines such as TGFβ secreted by the tumour (FIG. 2) , eliminating myeloid-derived suppressor cells (MDSCs), and providing essential growth factors and cytokines that are required for NK cell activation, proliferation and persistence. Strategies to address these issues are rapidly being developed and may improve NK cell-based therapies in the near future. (FIG. 3c) . Several recent studies have documented success using NK cells that were engineered to express activating chimeric antigen receptors (CARs) that are specific for tumour antigens 141 . In some studies, the NK-92 cell line (an NK cell leukaemia cell line) were transduced to express CARs specific for CD19 (REF. 142) and CD20 (REF. 143 ) expressed on B cell malignancies; disialoganglioside G D2 , a glycolipid expressed on neuroblastoma 144 and various other cancer types 145 ; HER2 (also known as ERBB2), an antigen expressed by tumours of epithelial origin [146] [147] [148] ; epithelial cell adhesion molecule (EPCAM), a molecule over expressed by carcinomas and cancer stem cells 149 ; HLA-A2 loaded with the mela noma antigen gp100 (also known as PMEL) 150 ; prostate stem cell antigen (PSCA) 151 ; and CD138 (also known as SYND1), which is expressed by multiple myeloma cells 152 . Because NK-92 cells are a tumour cell line infected with Epstein-Barr virus (EBV), they must be irradiated to prevent their proliferation before being adoptively transferred. For this reason, and also because NK-92 cells are allo geneic and have lost some important NK cell-activating receptors, including NCRs and CD16, other studies have used primary NK cells isolated from peripheral blood or derived from pluripotent stem cells 153, 154 . In these studies, primary human NK cells that were transduced to express CARs specific for CS1 (also known as SLAMF7; which is expressed on multiple myeloma cells) 155 , meso thelin (over expressed by ovarian cancer) 156 , CD19 , HER2 (REF. 160) and G D2 (REF. 161) showed increased responses to tumour cells in vitro and suppressed tumour growth when tested in vivo in xenograft models 162, 163 . Although initially considered as receptors providing 'built-in' ADCC-like NCRL activity against specific tumour antigens, CARs actually elicit a significantly stronger NK cell cytotoxic response than ADCC mediated by anti bodies against the same targets 164 . This may be because the ligand-binding portion of the CAR has higher affinity than the Fc region of the IgG antibody for the CD16 Fc receptor on NK cells and because the cytoplasmic domain of the CAR has been engineered to maximize intracellular signalling. Because of their shorter lifespan, CAR-expressing NK cells might be superior to T cells, as they would not need 'suicide genes' to limit their expansion, in that NK cells, unlike T cells, are not able to produce autocrine growth factors such as IL-2, and this may also limit off-target side effects by CAR-bearing NK cells 165 . Additionally, even if the targeted antigens were rapidly lost on tumours, CARexpressing NK cells would still be able to be stimulated by their endogenous activating receptors such as NKG2D, DNAM1 and NCRs. We look forward to the results of the Phase I clinical trials using primary NK cells expressing CARs for the treatment of leukaemia, as these will help to answer questions about how these modified NK cells behave in patients and compare with CAR-bearing T cells with respect to efficacy, longevity and side effects.
Conversely, because of their potent recognition of 'induced-self ' ligands expressed by some tumour cells, some NK cell-specific receptors are potential candidates for CAR-engineered T cells. Studies by Sentman and colleagues 166 have shown the in vitro efficacy of T cells expressing CARs based on NKG2D. These T cells are cytotoxic against tumour cells, but also against immunosuppressive myeloid cells and T Reg cells that transiently express NKG2DLs [167] [168] [169] . These 'improved' NKG2D CARs present advantages over the endogenous NKG2D receptors, because some of these CAR variants that do not associate with DAP10 (the signalling adaptor required for endogenous NKG2D receptor expression) are not down-modulated after exposure to the ligands 170 . Other NKG2D CAR variants enhance NK cell proliferation and cytokine production owing to their engineered signalling domains. However, a very serious concern with enhanced NKG2D CAR T cells is that NKG2DLs can be expressed on non-tumour tissues, which might cause autoimmune reactions. Indeed, a recent study reported that NKG2D CARs transduced into mouse T cells induced rapid lethal toxicity when adoptively transferred into an autologous mouse model 171 . As yet, there is limited experience in vivo with CAR-engineered NK cells to know the efficacy versus toxicity outcomes of this strategy.
Nonetheless, human T cells expressing a CD16-based CAR showed considerable antitumour activity when administered in combination with therapeutic anti bodies in xenograft models 172 . Promising studies using T cells expressing CARs based on other NK cell receptors such as NKp46 (REF. 173) or NKp30 (REF. 174) showed good efficacy against various tumours expressing their respective ligands, although again expression of undefined ligands on healthy cells in the host might result in undesired toxicities. In summary, NK cells are very promising candidates for CAR-based therapies owing to their vast array of activating receptors that trigger spontaneous lysis of tumours via natural cytotoxicity or ADCC, in addition to CAR-mediated activation. Further, these NK receptors themselves represent considerable opportunities for the design of various new CAR strategies in T cells.
NK cell-targeted bispecific antibodies. In addition to conventional antibodies that are specific for tumour antigens that elicit ADCC, some bispecific proteins have been designed to recognize tumour antigens on one arm and bind to activating NK cell receptors on the other arm (FIG. 3d) . The resulting crosslinking promotes the interaction between NK cells and tumour cells, while stimulating NK cells and triggering target cell lysis. Given the potency of ADCC, many of these bispecific proteins were designed in order to provide stronger and more stable binding to CD16 than the Fc region of conventional antibodies, given their relatively low affinity for CD16. Various approaches, such as using CD16-targeting Fv domains with higher affinity 175 and tetravalent proteins with two binding sites for CD16 for added stability 176 , have proved successful in redirecting NK cell lysis towards tumour cells. Different tumour types have been targeted by linking these anti-CD16 Fv domains to Fv domains against CD19 (REF. 177 ) and HLA class II for B cell malignancies 178 , CD30 for Hodgkin's lymphoma 176, 179 , epidermal growth factor receptor (EGFR), which is overexpressed in several epithelial cancer types 175 , HER2 (REFS 180, 181) for breast cancer, CD33 for AML 182, 183 and EPCAM 184 for carcinomas. The in vitro and in vivo efficacy of these optimized proteins in eliciting specific antitumour activity is encouraging and should be further developed in clinical settings.
Another NK cell receptor that has been targeted in bispecific protein design is NKG2D. One of these approaches was to create a bispecific protein that recognizes NKG2DLs expressed by tumour cells and CD3 in order to redirect T cell lysis 169 . Other NKG2D-based bispecific reagents have attempted to trigger NKG2D-dependent cytotoxicity using an NKG2DL on one arm and a tumour antigen-specific Fv domain on the other arm 185 . The first of this kind was a RAET1H-anti-CD138 fusion protein that bound to CD138, which is overexpressed in multiple myeloma 186 , and crosslinked NKG2D on NK cells. Similarly, a RAET1H-anti-carcinoembryonic antigen (CEA) bispecific protein showed significant in vitro and in vivo efficacy against colon carcinoma 187 . Another study used recombinant MICA conjugated to mono clonal antibodies specific for CEA, HER2 or CD20, and their use resulted in NKG2D-dependent tumour cell lysis by NK cells 188 . Because T cells also express NKG2D, all bi specific proteins targeting this receptor have the advantage of co-stimulating both NK and T cells, as demonstrated in a study that used a fusion protein containing RAET1H and Fv domains specific for CD33 to redirect NK and T cell lysis towards AML cells 189 . For this reason and because they use a pathway that tumours try to evade by various mech anisms, this versatile NKG2D-based bispecific approach is very promising.
Conclusions
NK cells have a crucial role in immunosurveillance against tumour formation. However, when both the innate and adaptive immune systems fail and tumours develop, NK cells and their receptors can still be targeted in many therapeutic approaches (FIG. 4) . From the adoptive transfer of genetically modified NK cells to optimization of the existing checkpoint blockade therapeutics and tumour antigen-specific antibodies and newly engineering bispecific molecules to engage an NK cell response, there are many opportunities to exploit NK cells in immunotherapeutic strategies to eliminate cancer. Many challenges remain, in particular that of over coming the tolerance mechanisms used by NK cells to 'do no harm to self ' . As such, it is important to continue the molecular and functional characterization of NK cells and their receptors, both at the bench and in clinical trials, so that future immunotherapies can be innovated and improved accordingly.
